Form 4: BioAge Labs Director Granted 22,000 Stock Options to Align Interests

BioAge Labs, Inc. director Michael H. Davidson was granted 22,000 stock options with an exercise price of $4.44, aligning his interests with shareholders.

Summary

• Michael H. Davidson, a Director of BioAge Labs, Inc. (BIOA), was granted 22,000 stock options.
• The transaction date for this grant was June 5, 2025.
• Each stock option has an exercise price of $4.44.
• The options are for the right to buy 22,000 shares of BioAge Labs Common Stock.
• The entire option award is set to vest on the earlier of the next annual meeting of the Issuer's stockholders or the one-year anniversary of the grant date (June 5, 2026), contingent on Mr. Davidson's continued service.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Mr. Davidson beneficially owns 22,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a standard insider transaction (stock option grant) which is generally viewed as neutral to slightly positive, as it aligns the director's interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options to a director, Michael H. Davidson, aligns his financial interests with those of the company's shareholders, incentivizing long-term value creation.
• Stock options are a common form of executive and director compensation, indicating standard corporate governance practices.

Future Outlook

The granted stock options are subject to a future vesting schedule, which will occur on the earlier of the next annual meeting of stockholders or the one-year anniversary of the grant date (June 5, 2026), provided the director continues their service to the company.

Industry Context

The granting of stock options to directors is a standard practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain talent while aligning leadership incentives with shareholder returns.

Comparison to Industry Standards

• The use of stock options as a component of director compensation is a common practice in the biotechnology sector, similar to companies like Moderna or BioNTech, which frequently utilize equity-based incentives.
• The vesting schedule, tied to continued service and an annual meeting, is a typical structure for such grants, comparable to those observed in many publicly traded companies aiming to ensure long-term commitment from their board members.

Corporate Governance

Related Party Transactions

• The grant of 22,000 stock options to Michael H. Davidson, a director of BioAge Labs, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's incentives with shareholder value, potentially leading to better long-term performance.
• Employees: No direct impact mentioned, but such compensation practices can set precedents for broader equity incentive programs.

Next Steps

• The stock options will vest on the earlier of the next annual meeting of BioAge Labs' stockholders or June 5, 2026, subject to Michael H. Davidson's continued service.

Key Dates

Keywords

BioAge Labs, BIOA, Stock Option, Insider Transaction, Director Compensation, Form 4, Equity Grant, Vesting